STADA Arzneimittel AG
https://www.stada.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From STADA Arzneimittel AG
Calliditas Confident Of Setanaxib's Potential Despite Unclear Data
The Sweden-headquartered biotech has emphasized the promising survival data in a head and neck cancer study of setanaxib rather than the NOX inhibitor’s inability to shrink tumors.
Stada Tight-Lipped On Potential Sale Amid Reports Talks Are Underway
The rumor mill is heating up on Stada’s potential sale by its owners, Bain Capital and Cinven, after seven years at the helm.
Is Stada Laying The Ground For Future Sale With Russia Business Spin Off?
With the war in Ukraine now in its third gruelling year, Stada has announced that it last year siphoned off its Russian interests to its parent company Nidda in a non-cash deal.
Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval
Stada has revealed details of exactly when in 2024 it plans to launch its Alvotech-partnered Uzpruvo ustekinumab biosimilar to Stelara, having just been granted a pan-European marketing authorization. At the same time, the German firm has also struck a distribution deal for prescription and consumer healthcare products with Zuellig in the Philippines.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice